SUMMARY

Drugs that are structural mimetics of peptides (e.g. small molecules) have been plagued by problems associated with oral availability and transcellular movement. Vector-mediated transport, where a potentially therapeutic drug is covalently linked to another molecule that is a ligand for an active transport or transcytosis system, was developed as an approach for moving a drug across the blood-brain-barrier. We now report a vector approach that produced peptides with oral activity, blood-brain-barrier transport, and extended in vivo half-life. Generating these properties requires secondary structure stabilization into a β hairpin, and the addition of a C-terminal dipeptide sequence composed of non-polar residues. Peptides with biological activity incompatible with these derivatizations were covalently linked to a model transport vector, producing a chimera with the therapeutic activity of the peptide and the transport properties of the vector. Our platform technology may be a general approach for the design of drug-like peptides.

Copyright

The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.